CTNM Profile
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative oral small molecule therapies targeting neuroscience, inflammation, and immunology with significant unmet medical needs. Founded in 2009 and headquartered in San Diego, California, Contineum Therapeutics is advancing a range of novel therapies designed to address complex and challenging conditions.
The company's leading asset is PIPE-791, a brain-penetrant small molecule inhibitor targeting the lysophosphatidic acid 1 receptor (LPA1R). This drug is currently being evaluated for its potential in treating idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS), two conditions with limited effective treatment options. PIPE-791's unique mechanism of action aims to offer new therapeutic possibilities for patients suffering from these debilitating diseases.
Contineum Therapeutics is also developing PIPE-307, a selective small molecule inhibitor of the muscarinic type 1 (M1) receptor. This compound is being investigated for its efficacy in treating depression and relapse-remitting MS. Additionally, the company is working on CTX-343, a peripherally-restricted LPA1R antagonist, which is expected to complement its existing pipeline by targeting different pathways involved in inflammation and immune response.
Formerly known as Pipeline Therapeutics, Inc., the company rebranded to Contineum Therapeutics, Inc. in November 2023 to better reflect its focus and strategic vision. Through its robust pipeline and innovative drug development programs, Contineum Therapeutics aims to address critical gaps in treatment and provide new options for patients with severe and unmet medical needs.
|
